CN1427721A - 肽脱甲酰基酶抑制剂 - Google Patents

肽脱甲酰基酶抑制剂 Download PDF

Info

Publication number
CN1427721A
CN1427721A CN01808997A CN01808997A CN1427721A CN 1427721 A CN1427721 A CN 1427721A CN 01808997 A CN01808997 A CN 01808997A CN 01808997 A CN01808997 A CN 01808997A CN 1427721 A CN1427721 A CN 1427721A
Authority
CN
China
Prior art keywords
hydroxy
formyl
ethylamine
group
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01808997A
Other languages
English (en)
Chinese (zh)
Inventor
凯利·M·奥巴特
西格弗里德·B·克里斯坦森第四
雅克·布赖恩德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1427721A publication Critical patent/CN1427721A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/14—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN01808997A 2000-05-05 2001-05-04 肽脱甲酰基酶抑制剂 Pending CN1427721A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20194300P 2000-05-05 2000-05-05
US60/201,943 2000-05-05
US23808400P 2000-10-04 2000-10-04
US60/238,084 2000-10-04

Publications (1)

Publication Number Publication Date
CN1427721A true CN1427721A (zh) 2003-07-02

Family

ID=26897227

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01808997A Pending CN1427721A (zh) 2000-05-05 2001-05-04 肽脱甲酰基酶抑制剂

Country Status (20)

Country Link
US (2) US6806369B2 (enExample)
EP (1) EP1283711B1 (enExample)
JP (1) JP2003532677A (enExample)
KR (1) KR20020093127A (enExample)
CN (1) CN1427721A (enExample)
AR (1) AR029916A1 (enExample)
AT (1) ATE389403T1 (enExample)
AU (1) AU2001261218A1 (enExample)
BR (1) BR0110206A (enExample)
CA (1) CA2408236A1 (enExample)
CZ (1) CZ20023618A3 (enExample)
DE (1) DE60133273T2 (enExample)
ES (1) ES2300330T3 (enExample)
HU (1) HUP0302505A2 (enExample)
IL (1) IL152638A0 (enExample)
MX (1) MXPA02010843A (enExample)
NO (1) NO20025281L (enExample)
NZ (1) NZ521560A (enExample)
PL (1) PL359865A1 (enExample)
WO (1) WO2001085170A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967220B2 (en) * 2001-04-05 2005-11-22 Smithkline Beecham Corporation Peptide deformylase inhibitors
ES2374664T3 (es) * 2001-06-05 2012-02-20 Glaxosmithkline Llc Inhibidores de péptido desformilasa.
AU2003296960A1 (en) * 2002-12-11 2004-06-30 Smithkline Beecham Corporation Peptide deformylase inhibitors
EP1683521A1 (en) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same
JP2008538776A (ja) * 2005-04-25 2008-11-06 ノバルティス アクチエンゲゼルシャフト ペプチド脱ホルミル酵素（ｐｄｆ）阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
US7705037B2 (en) * 2005-06-07 2010-04-27 Novartis Ag 1-substituted pyrrolidin-2-ones and use thereof as peptide deformylase inhibitors
WO2007040289A1 (en) * 2005-10-05 2007-04-12 Promeditech Inc. Deformylase inhibitor, process for the preparation thereof, and composition comprising the same
KR100753796B1 (ko) * 2006-07-28 2007-08-31 주식회사 프로메디텍 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282986A (en) 1960-10-06 1966-11-01 Merck & Co Inc N-acylated hydroxamic acids and derivatives thereof
PT82200B (pt) 1985-03-16 1990-02-08 Wellcome Found Processo para a preparacao de novos derivados do acido hidroxamico e de composicoes farmaceuticas que os contem
GB8531838D0 (en) 1985-12-30 1986-02-05 Wellcome Found Aryl derivatives
PL154186B1 (en) 1987-07-15 1991-07-31 Wellcome Found Method for manufacturing arylic derivatives of the hydroxamic acid
BR9810760A (pt) 1997-07-31 2001-11-27 Abbott Lab Inibidores de hidroxamato reverso demetaloproteinases de matriz
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
CA2320476A1 (en) 1998-02-07 1999-08-12 British Biotech Pharmaceuticals Limited Antibacterial agents
AR028075A1 (es) * 2000-05-05 2003-04-23 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
US20040034024A1 (en) 2001-05-04 2004-02-19 Aubart Kelly M Peptide deformylase inhibitors

Also Published As

Publication number Publication date
US7115605B2 (en) 2006-10-03
DE60133273T2 (de) 2009-03-05
HUP0302505A2 (hu) 2003-12-29
IL152638A0 (en) 2003-06-24
PL359865A1 (en) 2004-09-06
JP2003532677A (ja) 2003-11-05
EP1283711A1 (en) 2003-02-19
EP1283711A4 (en) 2003-05-21
NO20025281D0 (no) 2002-11-04
CA2408236A1 (en) 2001-11-15
BR0110206A (pt) 2003-01-28
AR029916A1 (es) 2003-07-23
EP1283711B1 (en) 2008-03-19
NZ521560A (en) 2004-05-28
MXPA02010843A (es) 2003-03-27
NO20025281L (no) 2003-01-03
CZ20023618A3 (cs) 2003-09-17
ATE389403T1 (de) 2008-04-15
ES2300330T3 (es) 2008-06-16
WO2001085170A1 (en) 2001-11-15
KR20020093127A (ko) 2002-12-12
US6806369B2 (en) 2004-10-19
WO2001085170A9 (en) 2006-01-26
DE60133273D1 (de) 2008-04-30
AU2001261218A1 (en) 2001-11-20
US20040192719A1 (en) 2004-09-30
US20040053932A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
CN1427721A (zh) 肽脱甲酰基酶抑制剂
US7745637B2 (en) Peptide deformylase inhibitors
EP1283709B1 (en) Peptide deformylase inhibitors
US20040267015A1 (en) Peptide deformylase inhibitors
US6797730B2 (en) Peptide deformylase inhibitors
JP4266815B2 (ja) ペプチドデホルミラーゼ阻害剤
US6897233B2 (en) Peptide deformylase inhibitors
US20040034024A1 (en) Peptide deformylase inhibitors
JP2005532358A (ja) ペプチドデホルミラーゼ阻害剤
US20060025412A1 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication